VVOSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Vivos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.13+0.00 (+2.90%)
Close on Oct 19, 2026
- Market cap
- $2.39M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
60.4%−19.3 pts over 5 years
Operating margin
-114.1%−21.9 pts over 5 years
Net margin
-121.4%−29.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +16.0% | +2.9% | +5.9% | – | |
| Gross profit | +16.9% | +1.7% | +0.2% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -172.6% | -655.0% | |
| Return on assets | – | -73.3% | -104.7% | |
| Current ratio | – | 2.60 | 0.24 | |
| Debt to equity | – | 0.08 | -5.92 | |
| Net debt to EBITDA | – | 1.49× | -0.37× | |
| Interest coverage | – | -125.4× | -14.2× | |
| Capex to revenue | – | 0.9% | 13.4% | |
| Diluted shares | – | 1M | 10M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Vivos Therapeutics generated $75.22M from operations and spent $7.03M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$75.22M
Used
$7.03M
Capital expenditure$7.03M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-121.4%
×Asset turnover0.86×
×Equity multiplier6.26×
=Return on equity, FY2025-655.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -121.4% | 0.86× | 6.26× | -655.0% |
| FY2024 | -74.1% | 1.16× | 3.11× | -266.3% |
| FY2023 | -98.4% | 1.13× | 4.69× | -521.2% |
| FY2022 | -148.8% | 0.68× | 1.56× | -157.2% |
| FY2021 | -120.2% | 0.57× | 1.39× | -95.6% |
| FY2020 | -92.3% | 0.79× | 2.35× | -172.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$21.17M
- Cash generatingOperating cash flow above zero-$15.26M
- Return on assets improvedROA up on the prior year-103.8% → -138.5%
- Earnings backed by cashOperating cash flow above net income-$15.26M vs -$21.17M
- Less leverageLong-term debt to assets fell7.9% → 1.9%
- Better liquidityCurrent ratio rose1.50 → 0.24
- No dilutionShare count did not rise5M → 10M
- Gross margin improvedGross margin up on the prior year60.00% → 60.44%
- More efficientAsset turnover rose1.40 → 1.14